Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Be Well Clinical Studies

Neither a doctor nor a teaching hospital

Research payments

$1,884,717

613 payments

Through program year 2025, Be Well Clinical Studies is reported as receiving $1,884,717 in research payments, across 613 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $265,695 13
2024 Research $234,482 13
2023 Research $342,507 29
2022 Research $822,988 521
2021 Research $219,046 37

Breakdown

Who paid Research payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $584,122 85 payments
  2. Moderna TX, Inc. $475,779 475 payments
  3. Pfizer Inc. $472,725 39 payments
  4. AstraZeneca UK Limited $154,199 5 payments
  5. Amgen Inc. $126,845 3 payments
  6. AstraZeneca Pharmaceuticals LP $47,900 2 payments
  7. Celgene Corporation $19,000 1 payment
  8. E.R. Squibb & Sons, L.L.C. $4,147 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $417,605 24 payments
  2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $322,085 44 payments
  3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $245,403 462 payments
  4. Study name not reported $219,046 37 payments
  5. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $173,717 6 payments
  6. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $130,874 4 payments
  7. A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM $93,448 1 payment
  8. A Phase 12 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Group B Streptococcus Vaccine in Healthy Nonpregnant Women and Pregnant Women 18 to 40 Years of Age and Their Infants $54,485 10 payments
  9. a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $47,900 2 payments
  10. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $46,258 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record